论文部分内容阅读
自1985年Rubin等发现可溶性白细胞介素2受体(SIL—2R)以来,有关它与免疫性疾病的关系研究进展十分迅速,普遍认为SIL—2R可作为临测某些与免疫有关的疾病病情和活动情况的指标,而关于SIL—2R与某些心血管疾病的关系亦有少数报道,但对于它与冠心病的关系却罕见报道。本文采用酶标双抗体夹心法测定52例CHD患者血清SIL—2R水平的变化,以探讨它们之间的关系及临床意义。 1 对象与方法 1.1 研究对象:CHD组:共52例,男39例,女13例,平均年龄63.5岁。其中心功能(按NYHA分
Since the discovery of soluble interleukin-2 receptor (SIL-2R) by Rubin et al in 1985, the research on its relationship with immune diseases has progressed rapidly. It is generally accepted that SIL-2R can be used as a test for some immune-related diseases And activity indicators, and SIL-2R and some cardiovascular disease also reported a small number of reports, but its relationship with coronary heart disease is rarely reported. In this paper, enzyme-linked double antibody sandwich method for the determination of serum levels of SIL-2R in 52 CHD patients to explore the relationship between them and clinical significance. 1 Subjects and methods 1.1 Study: CHD group: a total of 52 cases, 39 males and 13 females, with an average age of 63.5 years. Its central function (by NYHA points